Active substance
Carbinoxamine
- US FDA 14
- US price lines 2
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CARBINOXAMINE MALEATE | 4MG/5ML | solution · oral | GENUS | Prescription | 25 Apr 2003 |
| CARBINOXAMINE MALEATE | 4MG | tablet · oral | STRIDES PHARMA INTL | Prescription | 30 May 2008 |
| CARBINOXAMINE MALEATE | 4MG | tablet · oral | MISSION PHARMACAL | Prescription | 27 May 2011 |
| KARBINAL ER | 4MG/5ML | suspension, extended release · oral | AYTU | Prescription | 28 Mar 2013 |
| CARBINOXAMINE MALEATE | 6MG | tablet · oral | PHARMOBEDIENT | Prescription | 31 May 2016 |
| CARBINOXAMINE MALEATE | 6MG | tablet · oral | LEADING | Prescription | 19 Dec 2024 |
| CARBINOXAMINE MALEATE | 4MG | tablet · oral | GENUS LIFESCIENCES | Discontinued | 19 Mar 2003 |
| CARBINOXAMINE MALEATE | 4MG/5ML | solution · oral | PH HEALTH | Discontinued | 26 Feb 2008 |
| CARBINOXAMINE MALEATE | 4MG | tablet · oral | STRIDES PHARMA INTL | Discontinued | 30 May 2008 |
| CARBINOXAMINE MALEATE | 4MG | tablet · oral | SENORES PHARMS | Discontinued | 15 Apr 2010 |
| CARBINOXAMINE MALEATE | 4MG/5ML | solution · oral | CYPRESS PHARM | Discontinued | 4 May 2010 |
| CARBINOXAMINE MALEATE | 4MG | tablet · oral | CYPRESS PHARM | Discontinued | 23 Aug 2010 |
| CLISTIN | 4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ORTHO MCNEIL PHARM | Discontinued | |
| CLISTIN | 4MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | elixir · oral | MCNEIL | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CARBINOXAMINE ER 4 MG/5 ML SUSP | $1.04689 | per ML | 23 Sep 2026 |
| US NADAC | CARBINOXAMINE MALEATE 4 MG TAB | $0.39806 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 25 Mar 2021 KARBINAL ER — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.